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We investigated the contribution of genetic variations in CDH13 to adiponectin 
level in patients with statin treatment. A variation of CDH13 (rs3865188) was 
genotyped in 345 Korean patients. We divided them into two groups; statin-free 
group versus statin group. There were differences in the distributions of alleles 
and genotypes between each group. The genetic variation of CDH13 gene 
showed a significant correlation with several clinical factors, such as adiponectin, 
diastolic blood pressure (DBP), triglyceride (TG), and insulin. Patients with the TT 
had significantly lower adiponectin level than those with AA (p = 0.046). The 
fasting blood sugar (FBS) was lower in patients with TT than those with AA (p= 
0.026). The highest TG was observed in the patients with TT compared with AA 
in statin-free group (p = 0.025). In statin-free group, we observed a significant 
difference of adiponectin level between patients with A allele and those with T 
allele (p = 0.007), while there was no difference of adiponectin level in statin 
group. In linear regression analysis, BMI and insulin were negatively correlated 
with adiponectin level in patients with A allele only regardless of statin group 
(p=0.011 vs, p=0.003, respectively). Whereas, triglyceride was associated with 
adiponectin in patients with T allele of statin-free group (p<0.001). In statin group, 
BMI, TG, and insulin could explain the usual decrease in adiponectin in patients 
with A allele (p=0.002, p=0.009, and p=0.003, respectively) not T allele. We 
identified an association between variants of CDH13 rs3865188 and adiponectin 
level in Korean patients with statin treatment. 
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Perfluorooctane sulfonate (PFOS) is synthetic fluorinated hydrocarbons. 
However the carbon-fluoride bonds render these compounds to be non-
biodegradable, leading to their persistence in the environment and lengthy 
elimination half-life in vivo. PFOS could also penetrate the placental barrier and 
the blood brain barrier, and produce neurotoxic effect. High dose of PFOS leads 
to neonatal mortality and neurologic delays. It is known PFOS generate a dose-
dependent ROS production, but the effect in PUFA lipid peroxidation, especially 
adrenic, arachidonic, docosahexaenoic and eicosapentaenoic acids that are 
important for cerebral development is not well investigated.    In this study, we 
evaluated oxidised lipid products (F2- and F3-isoprostanes, F4-neuroprostanes, 
F2-dihomo-isoprostanes, dihomo-isofuran, HETEs, RvD1) of arachidonic, 
eicosapentaenoic, docosahexaenoic and adrenal acids in liver of maternal CD-1 
mice treated with vehicle (control), 0.3 or 3 mg/kg/day PFOS for 21 days and 
after 7 days washout period. Fetal liver of male and female pups were also 
assessed upon in utero PFOS exposure to the maternal mice.   Exposure of 
PFOS reduced liver arachidonic, eicosapentaenoic, docosahexaenoic and 
adrenic acids level in maternal and pup. Oxidized lipid products, in particular F2-
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isoprostanes, F4-neuroprostanes F2-dihomo-isoprostanes and dihomo-isofuran 
elevated in liver of maternal mice exposed to PPFO at both concentrations 
compared to control. The levels did not recede after 7 days washout period and 
instead increased further. Concentration of the oxidized lipid products, notably 
F2- and F3-isoprostanes were also high in pup livers compared to control. 
Concentration of liver of female pups were higher than male.   This study 
indicates exposure of PFOS altered PUFA metabolism and induced liver lipid 
peroxidation in maternal mice. Such effect can be transferred to fetus and cause 
toxicity that may lead to detrimental effect on neurological development. 
 
 
Omega-3s in TBI and Post-Concussive Syndrome (TUESDAY, N12.07) 
 
Presenter Last Name: Lewis 
 
Background. Traumatic brain injury (TBI), with its diverse heterogeneity and 
prolonged secondary pathogenesis, remains a clinical challenge. Post-
concussive syndrome (PCS) remains an enigma as well. Currently, there are no 
effective treatments for either. Management focuses on acute surgical and 
intensive care, long-term rehabilitation, and treatment of symptoms. Promising 
treatments have failed to translate clinically as they typically target single 
pharmacologic targets rather than considering the multiple mechanisms of the 
injury and a more holistic approach to the brain itself. A combination therapy 
influencing multiple aspects of neuroprotection, neuroinflammation, and 
neuroregeneration is needed. Omega-3 fatty acids (ω-3FA) offer the advantage 
of a poly-target approach. Eicosanoid, decosanoid, and resolvin biochemical 
pathways positively influence neuronal cell survival and neuroinflammation and 
promote remyelination, neurogenesis, and synaptogenesis.    Methods. An 
unpublished pilot study of PCS patients using EEG brain-mapping and 
neurocognitive testing pre- and post-therapy with five weeks of high dose ω-3FA 
are detailed.    Results. Brainmapping and neurocognitive testing demonstrate 
significant objective improvement in PCS subjects post- ω-3FA therapy as 
compared to baseline. Based on these results and experience, proposed clinical 
protocols are presented for TBI and PCS.   Conclusions. The brain needs to be 
saturated with high doses of ω-3FA in order to have the best opportunity to heal 
following injury. This is substantiated with EEG brain-mapping and 
neurocognitive testing. Although further clinical research is needed, there is a 
growing body of experience suggesting ω-3FA are beneficial in TBI as well as for 
those who continue to suffer the longer term symptomatic consequences. 
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